Pfizer stock slipped Thursday on a report it cut expectations for coronavirus vaccine deliveries in 2020 due to supply-chain issues.for its new key drug to pesa plus the CFO of Chegg tells us how the company aims tohttps://imasdk.googleapis.com/js/core/bridge3.427.1_en.html#goog_1783924639Volume 0%
As recently as September, Pfizer (PFE) and BioNTech (BNTX) publicly said they anticipated producing up to 100 million doses of their coronavirus vaccine in 2020 and up to 1.3 billion in 2021. But, on Nov. 9, the duo changed their tune, saying in a news release they could make 50 million doses this year.
The report from the Wall Street Journal tugged on Pfizer stock. Pfizer spokeswoman Jerica Pitts confirmed to Investor's Business Daily that it experienced some supply-chain issues that put the 100 million manufacturing expectation for 2020 out of reach.
"Scale up of raw material took a little longer than was expected," she said. "Then, we had to think about the outcome of our clinical trial which was a little later than expected. That had some implications. But yes, the raw material did take longer."
https://www.aysim.net/wp-content/uploads/2020/12/Pfizer.jpg
Pfizer stock slipped Thursday on a report it cut expectations for coronavirus vaccine deliveries in 2020 due to supply-chain issues.for its new key drug to pesa plus the CFO of Chegg tells us how the company aims tohttps://imasdk.googleapis.com/js/core/bridge3.427.1_en.html#goog_1783924639Volume 0% As recently as September, Pfizer (PFE) and BioNTech (BNTX) publicly said they anticipated producing up to 100 million doses of […]
0 Comments:
Post a Comment